L&C BIO (290650) Q1 2025 earnings summary

Executive summary

• Specializes in human tissue grafts, tissue-based medical devices, cosmeceuticals, and related CRO services, with a strong focus on R&D and global expansion.

• Main revenue from acellular dermal matrix (ADM) products for reconstructive surgery, with expanding indications and international certifications.

• Recent milestones include full acquisition of Chinese subsidiary, new product launches, and significant investments in production and R&D facilities.

Financial highlights

• Q1 2025 consolidated revenue: KRW 17.76 billion, down from KRW 72.09 billion in FY2024.

• Q1 2025 consolidated net loss: KRW -642 million, compared to FY2024 net profit of KRW 140.97 billion.

• Q1 2025 separate revenue: KRW 14.57 billion; separate net profit: KRW 658 million.

• Gross margin improved year-over-year, but operating loss recorded due to higher SG&A expenses.

• Basic EPS for Q1 2025: -19 KRW (consolidated), 29 KRW (separate).

Outlook and guidance

• Anticipates continued growth in regenerative medicine, medical devices, and cosmeceuticals, leveraging new product launches and expanded global presence.

• Regulatory changes and market expansion in Asia expected to drive demand for tissue-based products.

• Recent capital increases and convertible bond issuance to support R&D, facility expansion, and overseas operations.